CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Phase 2GX-03Positive
AI Analysis

Summary

Turn Therapeutics announced final Stage 2 design and data-driven expansion of its GX-03 Phase 2 program for atopic dermatitis treatment.

Clinical Trial Data

Phase

2

Importance:5/10
Sentiment:
0.30
Phase 2Atopic DermatitisClinical DevelopmentProgram Expansion
Related Companies

Read the original article

Published by yahoo_finance on July 7, 2026 12:05 PM

Read Original